Protagonist Therapeutics ( PTGX ) Reports Q3 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -5.08% and -52.88%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Bolt Biotherapeutics, Inc. ( BOLT ) Expected to Beat Earnings Estimates: Should You Buy?
Bolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kymera Therapeutics, Inc. ( KYMR ) Reports Q3 Loss, Misses Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -26.76% and -89.60%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics ( PTGX ) Expected to Beat Earnings Estimates: Should You Buy?
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron ( REGN ) Q3 Earnings and Revenues Surpass Estimates
Regeneron (REGN) delivered earnings and revenue surprises of +25.32% and +4.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
2 Top Dividend Kings Every Income Investor Should Own
These companies pay durable and steadily rising dividends.
This 2.7%-Yielding Dividend King Remains One of the Healthiest Income Stocks You Can Buy
Johnson & Johnson has a very healthy financial profile and growth prospects.
Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook - Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson ( NYSE:JNJ ) on Tuesday reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75. The pharmaceutical and medtech giant reported sales of $23.99 billion, up 6.8% year over year and beating the consensus of ...
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
PTGX shares jump 30% after reports that J&J is in talks to acquire the biotech firm amid ongoing negotiations.
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch - Johnson & Johnson ( NYSE:JNJ )
Health care giant Johnson & Johnson ( NYSE:JNJ ) has had a good year with its shares trading near all-time highs. The company looks to keep a trend of beating analyst estimates when third-quarter financial results are reported before market open Tuesday.
FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy - Johnson & Johnson ( NYSE:JNJ )
The Food and Drug Administration ( FDA ) has updated safety labeling for Johnson & Johnson's ( NYSE:JNJ ) Carvykti after receiving reports of immune effector cell-associated enterocolitis ( IEC-EC ) -a rare but serious complication seen in both clinical trials and postmarketing data.
Douglas Lane Adds $6 Million in J&J Stock Ahead of Earnings and Possible Biotech Deal
Douglas Lane & Associates, LLC disclosed a purchase of 34,948 shares of Johnson & Johnson ( NYSE:JNJ ) in an SEC filing on Friday, representing an estimated $6 million transaction based on average prices during the third quarter.According to an SEC filing released on Friday, Douglas Lane & ...
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today
The company could soon be swallowed by a very large peer -- which also happens to be a business partner.
Why Is Protagonist Therapeutics Stock Soaring Friday? - Protagonist Therapeutics ( NASDAQ:PTGX ) , Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson ( NYSE:JNJ ) is reportedly in discussions to acquire Protagonist Therapeutics ( NASDAQ:PTGX ) . Citing people close to the talks, the Wall Street Journal reported that the deal is not guaranteed, and the terms have yet to be finalized.
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials - Johnson & Johnson ( NYSE:JNJ )
Icotrokinra outperformed deucravacitinib in skin clearance at Weeks 16 and 24 with similar or fewer adverse events. At Week 52, 86% of adolescents on icotrokinra achieved PASI 90 response, showing sustained effectiveness. Up Next: Wall Street trader's 34-0 strategy goes public this week.
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Biohaven ( NYSE:BHVN ) , Avient ( NYSE:AVNT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
J&J seeks EMA's nod to icotrokinra for treating plaque psoriasis in adults and pediatric patients aged 12 years and older.
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday - Protagonist Therapeutics ( NASDAQ:PTGX ) , StandardAero ( NYSE:SARO )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B. Riley Securities analyst Mayank Mamtani initiated coverage on Theravance Biopharma, Inc.
Protagonist ( PTGX ) Q2 Revenue Falls 26%
Protagonist Therapeutics ( NASDAQ:PTGX ) , a clinical-stage biotechnology company developing peptide-based therapies for blood and immune diseases, released second quarter results on August 6, 2025. The most significant news from the release was the company's continued advancement of its ...
Protagonist Therapeutics ( PTGX ) Reports Q2 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.77% and -46.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque psoriasis.
Tango Therapeutics ( TNGX ) Moves 7.5% Higher: Will This Strength Last?
Tango Therapeutics (TNGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis.
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study - Protagonist Therapeutics ( NASDAQ:PTGX ) , Johnson & Johnson ( NYSE:JNJ )
77% of genital psoriasis patients saw clear/almost clear skin vs. 21% on placebo after 16 weeks. PN-881 showed 70x greater potency than secukinumab in vitro and effective reduction in skin inflammation in rat models.
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance ( IGA 0/1 ) and a favorable safety ...
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Keros Therapeutics ( NASDAQ:KROS )
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Protagonist Therapeutics ( PTGX ) Reports Q1 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 62% and 149.90%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Johnson & Johnson Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson JNJ will release earnings results for the first quarter, before the opening bell on Tuesday, April 15. Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.58 per share, down from $2.71 per share in the year-ago period.
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study - Protagonist Therapeutics ( NASDAQ:PTGX ) , Johnson & Johnson ( NYSE:JNJ )
84.1% of adolescents on icotrokinra achieved clear/almost clear skin at Week 16 vs. 27.3% on placebo in Phase 3 PsO study. By Week 24, 75% of adolescents on icotrokinra had completely clear skin ( IGA 0 ) , with no new safety issues reported.
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics ( PTGX ) : Can the Stock Really Move This High?
The consensus price target hints at a 27.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week ( Mar 10-Mar 14 ) : Are The Others In Your Portfolio? - D-Wave Quantum ( NYSE:QBTS ) , IonQ ( NYSE:IONQ )
D-Wave Quantum soared 95.95% on a 502% YoY increase in Q4 bookings to $18.3M. Protagonist Therapeutics jumped 42.84% after its Phase 2b ANTHEM-UC study met primary endpoints. Next: Get access to a new market-moving chart every day featuring a stock flashing clear technical signals.
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Novo Nordisk, Roche, Pfizer, Arvinas and J&J are part of the Zacks top Analyst Blog.
Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
TSVT and PTGX are in the spotlight this week following an acquisition agreement and study data, respectively.
Protagonist Therapeutics ( PTGX ) Upgraded to Buy: Here's Why
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Asana ( NYSE:ASAN ) , AvePoint ( NASDAQ:AVPT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Citigroup cut AvePoint, Inc. AVPT price target from $18 to $16. Citigroup analyst Fatima Boolani maintained ...
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday - The Campbell's ( NASDAQ:CPB ) , Archer-Daniels Midland ( NYSE:ADM )
U.S. stocks were lower, with the Nasdaq Composite falling around 650 points on Monday. Shares of Redfin Corporation RDFN rose sharply during Monday's session after Rocket Companies announced it will acquire the company in an all-stock transaction valued at $12.50 per share.
Why Is Protagonist Therapeutics Stock Trading Higher On Monday? - Protagonist Therapeutics ( NASDAQ:PTGX ) , Johnson & Johnson ( NYSE:JNJ )
In the ANTHEM-UC study, 63.5% of patients on the highest icotrokinra dose achieved a clinical response at Week 12 vs. 27.0% on placebo. In the ICONIC-LEAD study, 65% of icotrokinra-treated psoriasis patients achieved clear or almost clear skin vs. 8% on placebo at Week 16.
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer - Protagonist Therapeutics ( NASDAQ:PTGX ) , Takeda Pharmaceutical Co ( NYSE:TAK )
77% of rusfertide patients achieved response vs. 33% on placebo at weeks 20-32. Rusfertide patients had 0.5 phlebotomies vs. 1.8 in the placebo group over 32 weeks. Our government trade tracker caught Pelosi's 169% AI winner. Discover how to track all 535 Congress member stock trades today.
Protagonist Therapeutics ( PTGX ) Tops Q4 Earnings and Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 3,200% and 202.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday - Atkore ( NYSE:ATKR ) , Carpenter Tech ( NYSE:CRS )
U.S. stocks were mixed, with the Dow Jones index gaining more than 150 points on Friday. Shares of Natural Grocers by Vitamin Cottage, Inc. NGVC rose sharply during Friday's session following quarterly results.
Protagonist Therapeutics ( PTGX ) Upgraded to Buy: Here's What You Should Know
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Protagonist Therapeutics ( PTGX ) Reports Q3 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 8.47% and 3.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Peptide Therapeutics Market to Witness 5.94% CAGR by 2031 | SkyQuest Technology
Westford, USA, Sept. 27, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that Peptide Therapeutics Market will attain the value of USD 68.4 Billion by 2031, with a CAGR of 5.94% during the forecast period ( 2024-2031 ) .
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines - Protagonist Therapeutics ( NASDAQ:PTGX )
Truist Securities initiated coverage on Protagonist Therapeutics Inc PTGX, citing its first-in-class lead asset with encouraging Phase 2 data in a rare form of blood cancer and a multi-billion dollar opportunity.
Protagonist Therapeutics ( PTGX ) Reports Q2 Loss, Misses Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 0% and 89.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AT&T, Group 1 Automotive, Mattel, Seagate And Other Big Stocks Moving Higher On Wednesday - Alkermes ( NASDAQ:ALKS ) , Avantor ( NYSE:AVTR )
U.S. stocks were lower, with the Dow Jones index falling around 350 points on Wednesday. Shares of AT&T Inc. T rose during Wednesday's session following second-quarter earnings.
Protagonist Therapeutics ( PTGX ) is on the Move, Here's Why the Trend Could be Sustainable
If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Protagonist Therapeutics Shows Market Leadership With Jump To 92 RS Rating
On Thursday, Protagonist Therapeutics ( PTGX ) hit an important technical milestone, with its Relative Strength ( RS ) Rating moving into the 90-plus percentile with an improvement to 92, an increase from 85 the day before. X IBD's proprietary rating measures market leadership with a 1 ( ...
